Abstract Research Article
TLRs also recognize locally produced damage-associated molecular patterns (DAMPs) from ischemic renal tissue and circulating DAMPs released from extensive extrarenal tissue damage in sepsis. [3] This triggers the activation of leukocytes, endothelial cells, and epithelial cells that release more inflammatory mediators such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6, IL-8, and IL-10, causing cellular and tissue damage. [4, 5] This situation of "cytokine storm" provides the basis for the concept of immunomodulation in the management of patients with severe sepsis. Treatment with low-dose corticosteroids accelerates septic shock reversal but is not associated with survival benefits. [6, 7] The clinical benefit of intravenous immunoglobulin and anti-TNF-α in the treatment of severe sepsis remains controversial and inconclusive. [8, 9] Extracorporeal blood purification therapies have been proposed to improve outcomes of patients with severe sepsis with or without acute kidney injury (AKI) by the removal of excessive inflammatory mediators from the blood compartment. [10, 11] Some inflammatory mediators have relatively large molecular size, i.e., 17 kDa for TNF-α, 26 kDa for IL-6, and 8 kDa for IL-8. Conventional high-flux hemofilter has a cutoff of approximately 20 kDa, which may not be able to achieve effective clearance for all relevant sepsis-related cytokines. [12, 13] High-cutoff (HCO) membranes have clinical cutoff points of 40-100 kDa. [14] In this regard, HCO hemofiltration has been reported to confer good cytokine clearance in patients with septic shock. [15] [16] [17] A literature review by Villa, which included five clinical studies, concluded that the removal of the inflammatory mediators by HCO technique was associated with a significant improvement in hemodynamic condition, oxygenation indices, and organ dysfunction. [18] We hereby report our experience with EMiC2 (Fresenius SE, Bad Homburg, Germany) HCO continuous venovenous hemofiltration (HCO-CVVH) or hemodialysis (HCO-CVVHD) in patients with severe septic shock complicated by AKI.
MaterIals and Methods
This study was a prospective case series from a 23-bed adult medical-surgical Intensive Care Unit (ICU) in a regional medical center in Hong Kong. The study was approved by the institutional ethics committee. We enrolled patients who fulfilled the following inclusion criteria: (1) age ≥18; (2) presence of septic shock as defined by the American College of Chest Physicians/Society of Critical Care Medicine/European Society of Intensive Care Medicine criteria; and [19] [20] [21] (3) presence of AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO). [22] pregnant patients, patients with documented chronic kidney disease Stage 5 (glomerular filtration rate <15 mL/min/1.73 m 2 ) or end-stage renal failure on long-term dialysis, terminally ill patients with life expectancy ≤3 months, and those with contraindications for regional citrate anti-coagulation (liver failure or liver cirrhosis, allergy to citrate) were excluded from the study. Informed consent was obtained from patients or their close relatives/surrogates before initiation of CVVH/CVVHD. Demographic data, comorbidities, and diagnoses were recorded. All patients received conventional therapy for severe sepsis, namely, infective source control, early appropriate antibiotics, fluid challenge and vasopressor infusion, and lung-protected ventilatory strategy based on the Surviving Sepsis Campaign guidelines. [19] A double-lumen 12-F HD catheter (ARROWguard blue plus antimicrobial catheter, Arrow International Inc., USA or GamCath™ High Flow double-lumen catheter, Baxter-Gambro, Stockholm, Sweden) was inserted into either the internal jugular or femoral vein for vascular access by the attending intensivist/physician. HCO-CVVH or HCO-CVVHD was performed using EMiC2 hemofilter (Fresenius Medical Care, Bad Homburg, Germany) with either anticoagulant citrate dextrose solution or 4% trisodium citrate as anticoagulant (3-4 mmol of citrate/ citric acid per liter of blood withdrawn). The blood flow was maintained at 100-150 ml/min. Calcium replacement was provided by either calcium gluconate or calcium chloride solution infusion and was titrated to achieve a systemic ionized calcium (iCa) level of 1-1.2 mmol/L with postfilter iCa level of 0.25-0.3 mmol/L. [23] The overall fluid withdrawal rate was adjusted to achieve the desired fluid balance at the discretion of physician-in-charge. Each patient received at least one session of HCO treatment and further treatment sessions were conducted based on the clinician's decision. Disease severity was assessed with the Acute Physiology and Chronic Health Evaluation (APACHE) IV score. [24] Organ dysfunction was quantified using the Sequential Organ Failure Assessment (SOFA) score. [25] [26] Length of stay and survival data were obtained as outcome parameters. Patients' actual mortality was compared with APACHE IV score, and SOFA score predicted mortality. Both of which are widely used and validated ICU mortality prediction models developed from a large sample of ICU patients. [24, 25] 
Statistical analysis
Sample size calculations were not performed for this case series. Data were reported as frequencies, percentages, median, and interquartile range (IQR). Change of clinical and biochemical parameters over time was assessed with related samples Friedman's two-way analysis of variance by Ranks test. Multivariate analysis was not performed due to small sample size. All analyses were performed using the Statistical Package for the Social Sciences for Windows, version 20 (SPSS Inc., Chicago, IL, USA).
results
Between May 2013 and November 2015, seven patients were treated with EMiC2 HCO-CVVH/HCO-CVVHD. Table 1 demonstrates the baseline characteristics of the patients. Patients were aged from 40 to 89 years (median age: 61 years, IQR: 54-83) and were predominantly male (86%). Around 57% of them suffered from respiratory tract infection and the others had intra-abdominal sepsis. HCO treatments were initiated quite early with 86% of patients within KDIGO Stage 1 or 2. All of them had septic shock and required moderate-to-high dose vasopressor support on initiation of HCO treatment (median noradrenaline equivalent: 16.7 µg/min, IQR: 11.1-46.7). All patients had multiorgan failure with median SOFA score of 13 points (IQR: 12-15). They also had high disease severity as illustrated by the high SOFA score-predicted risk of death (median: 0.60, IQR: 0.46-0.82) and APACHE IV-predicted risk of death (median: 0.78, IQR: 0.53-0.82).
Five out of seven (71%) recruited patients received only one session of HCO treatment; the median treatment duration for all patients was 71 h (IQR: 49-72 h), [ Table 2 ]. The majority of them (71%) had HCO-CVVHD, while others received HCO-CVVH (29%). Figures 1 and 2 illustrate the changes in noradrenaline equivalent (P = 0.002) and the SOFA score (P = 0.001) during the first 72 h after the initiation of HCO treatment, which indicated clinical improvement.
Figures 3-5 illustrate the changes in cytokine levels (IL-6 with P < 0.001, IL-10 with P = 0.001, and TNF-α with P = 0.021) over time, which indicated good cytokine modulation. Changes in C-reactive protein were less predictable (P = 0.055), [ Figure 6 ]. Figure 7 illustrates the changes in the albumin level during the treatment period.
The median albumin level on initiation of HCO treatment was 21 g/L (IQR: [20] [21] [22] [23] [24] [25] [26] [27] ) and the trough level occurred at 2 h after the initiation of HCO treatment (median: 20 g/L, IQR: 19-25, P = 0.029). Albumin supplementation was not provided to any of the recruited patients. Patient 3 developed significant hemodynamic collapse after 22 h of HCO treatment, which required early termination of treatment. Citrate toxicity was excluded and the treating physician attributed this event to clinical deterioration of the underlying pneumonia. The patient was subsequently started on conventional citrate-based CVVH after stabilization but deteriorated again in subsequent days, which resulted in ICU mortality. For the other patients, HCO treatment was well tolerated as evidenced by the stable hemodynamic and progressive decrement of noradrenaline use during the treatment. All but one patient were discharged from the ICU. The actual hospital mortality rate was 29%, which was lower than that predicted by SOFA (actual-to-predicted risk of death = 0.43) and APACHE IV score (actual over predicted risk of death = 0.41). This case series summarizes our clinical experience on the use of an EMiC2 HCO hemofilter for the treatment of septic shock patients with AKI. Our findings show that patients who received HCO treatment could achieve good cytokine modulation. Clinical improvement was observed after 24-36 h of treatment as indicated by the reduction of vasopressor usage and SOFA score. Overall, the patient outcomes were satisfactory, as illustrated by the low standardized mortality ratio (actual-to-predicted risk of death) based on commonly used mortality prediction models. Compared with the APACHE IV standardized mortality ratio in our previous cases with septic shock that required renal replacement therapy (RRT) (0.74 among 186 patients who received standard therapy vs. 0.41 among 7 patients treated with EMiC2 HCO therapy, P = 0.0547), the outcome of patients who received EMiC2 HCO treatment appeared acceptable.
The specifications of some commonly used HCO filters are shown in Table 3 . The cutoff level of the EMiC2 HCO hemofilter (40 kDa) used in our patients was lower than that of the PSH1, P2SH, or HCO1100 hemofilter (45-60 KDa) studied previously. [15, 16, 32, 33] Therefore, we expect lower cytokine clearance and also less albumin loss. Moreover, the membrane structure of the polysulfone-based EMiC2 hemofilter differs from the other polyarylethersulfone-based HCO hemofilters (e.g., PSH1, P2SH, or HCO1100 hemofilters) in terms of protein retention capacity, which may again affect albumin loss. [35] Published clinical data on the use of EMiC2 hemofilter for septic patients are limited. Yaroustovsky et al. reported the use of selective LPS adsorption procedures (Toraymyxin PMX-F cartridges; Toray, Japan) in combination with hemodialysis using EMiC2 HCO hemofilter for cardiac surgical patients with severe sepsis. [27] Compared with those patients on standard treatments, patients on combination therapies showed significant hemodynamic and oxygenation improvement. Potential mortality benefit was also observed. However, the net benefit of EMiC2 hemofilter is not clear. Therefore, our data did provide further clinical information for this novel HCO hemofilter.
Morgera et al. published the first study on the use of HCO hemofiltration (PSH1, cutoff: 60 KDa, surface area: 0.6 m 2 , Gambro Corporate Research, Hechingen, Germany) among septic shock patients and showed good IL-6 (but not TNF-α) clearance with fair hemodynamic tolerance. [15] Restoration of peripheral blood mononuclear cell proliferation was also observed in septic patients treated with HCO hemofiltration using P2SH filter (P2SH, cutoff: 60 KDa, surface area: cytokine (IL-6 and IL-1Ra) levels. [16] Compared with the treatment group in Morgera et al.'s study, [16] our patients had poorer clinical status as illustrated by higher APACHE II score (median: 25 points; IQR: 22-32 for Morgera's treatment group, vs. median: 29 points; IQR: 25-38 for our patients) despite having similar noradrenaline usage (median: 0.30 µg/kg/min; IQR: 0.10-0.48 vs. median: 0.28 µg/kg/min; IQR: 0.23-0.82). The baseline IL-6 level was higher for our patients compared with the treatment group in Morgera's study (median: 1078 pg/ml; IQR: 78-1861, vs. median: 243 pg/ml; IQR: 58-574). We also demonstrated similar reduction in vasopressor usage during HCO treatment. The 28-day mortality for our patients was 14% versus 61% for the treatment group in Morgera's study. However, without a control group in our study, the net benefit of this new hemofilter could not be delineated. In fact, rapid improvement of the clinical and biochemical parameters could also be due to conventional sepsis treatments based on the recommendation from the Surviving Sepsis Campaign guideline (e.g., infective source control with surgery or interventional radiological procedures, early antibiotic administration, adequate fluid challenge, and appropriate vasopressor/inotropic therapy). [19] The largest RCT on the use of HCO hemofilter for treatment of sepsis was the High Cut-Off Continuous Veno-venous Haemodialysis in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome/Septic Shock (HICOSS) study, which was published in abstract form. [32] The estimated sample size was 120 patients and the patients were randomized to receive either HCO-CVVHD (HCO 1100, cutoff: 45-60 KDa, surface area: 1.1 m 2 , Gambro Corporate Research, Hechingen, Germany) or CVVHD using conventional high-flux hemofilter. The study was terminated early because of a lack of difference between groups after 81 patients had been recruited. There was no difference in 28-day mortality, vasopressor use, duration of mechanical ventilation, ICU length of stay, or albumin level between groups. [32] This underpowered RCT (due to premature termination) cannot provide a clear answer on the potential benefit of HCO hemofiltration/HD in septic patients, and a further large-scale prospective RCT is recommended.
Compared with cytokine hemoadsorption, high-volume hemofiltration, or coupled plasma filtration adsorption, the equipment used for HCO hemofiltration/HD is easily available in a general ICU. The associated technique (i.e., CVVH or CVVHD) is also well established and requires minimal extra training for successful implementation. The pore sizes of HCO membranes are 2-3 fold larger than conventional high-flux membranes (which have a pore size of 0.003-0.006 µm) and one-twentieth that of plasma filter membranes (which have a pore size of around 0.2 µm). [14] The nominal cutoff points for HCO membranes range from 60 to 150 kDa and the clinical cutoff points in the blood range from 40 to 100 kDa. [14] By increasing the pore size of the hemofilter membrane, the sieving coefficients (SCs) of various inflammatory mediators increase significantly at the expense of the loss of albumin (66 kDa), antithrombin-III (60 kDa), protein C (62 kDa), and many other Figure 5: Tumor necrosis factor-alpha (pg/mL) changes during high-cutoff treatment. P = 0.021 for tumor necrosis factor-alpha changes over time, cases 3 and 4 were hospital nonsurvivors vital proteins. [36] Reducing the pore size slightly can limit vital protein loss, but this also decreases cytokine removal. These membranes are usually made from polyarylethersulfone/ polyethersulfone, polysulfone, or cellulose triacetate. [14] Initial ex vivo studies showed that the SCs for TNF-α (17 kDa, 27%-78%), IL-6 (26 kDa, 54%-99%), and IL-1 β (17 kDa, 58-81%) are very good. [15, [37] [38] [39] [40] A systematic review by Atan et al. on ex vivo studies showed that HCO hemofiltration displayed the greatest consistency in cytokine removal when compared with standard hemofiltration. [41] Albumin loss was comparable between HCO hemofiltration, HCO HD, and HCO hemodiafiltration, [41] but cytokine clearance may be better with a convective technique. [34] For our patients, the median albumin level decreased by <5% (21 to 20 g/L) during the HCO treatment period and therefore albumin replacement might not be necessary. This albumin drop may be related to HCO treatment, but hemodilution or redistribution into the extravascular space can be the cause as well. With continued HCO treatment, hemofilter clogging occurs due to the deposition of protein and red cells on the membrane surface. [18] This decreases the SC of larger molecules and also limits albumin loss. [18, 42] Limitations First, this case series is limited by the small sample size. However, the clinical experience of this novel EMIC2 HCO hemofilter is limited. Our data could provide a useful add-on for this field of study. Second, the cytokine assay was not readily available before randomization and therefore we could not target patients with hypercytokinemia who might be more responsive to the cytokine reductive therapy. Third, changes in cytokine levels might be contributed by decreased production from inflammatory cells in response to the appropriate treatment for sepsis per se. Cytokine assay within effluents should be useful to quantify RRT-associated removal, but this technique is not available locally. The clinical improvement observed could also be due to the effect of conventional treatments including antibiotics, other supportive measures, and infection source control. Without a control group in our study, the net benefit of this new hemofilter could not be ascertained. Finally, this was a single-center study in which local practice on the management of septic patients might alter the final clinical outcome. We followed the Surviving Sepsis Campaign guidelines closely to minimize this confounding factor. [19] conclusIon This case series shows that HCO-CVVH/CVVHD using EMiC2 hemofilter may provide good cytokine modulation, when used along with good quality standard sepsis therapy. A further large-scale prospective RCT is recommended to delineate the potential beneficial effect of this novel treatment in septic shock patients with or without renal impairment.
